Related Content
- Pfizer forms licensing agreement with Seattle Genetics
- Adherence among chronic disease patients can lead to big savings
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Medication adherence could be blockbuster for specialty
FOSTER CITY, Calif. — Drug maker Gilead Sciences plans to buy out a privately owned Seattle company that makes treatments for cancer and inflammatory diseases, Gilead said Tuesday.
The Foster City, Calif.-based company will buy Calistoga Pharmaceuticals for $375 million, plus additional milestone payments of up to $225 million.
Calistoga is currently developing CAL-101, which is in phase-2 studies, as a treatment for leukemia and non-Hodgkin’s lymphoma. The company specializes in drugs that target PI3K, an enzyme pathway that helps control the reproduction, survival and activity of cells.
